The ambiguous nature of AP-1 determined by a delicate balance in the subunit composition is most likely to blame for a decline in the number of studies since 1990s considering AP-1 as a promising cancer-specific therapeutic target and diagnostic factor. The gene discussed is FOS; the disease is cancer.